ReviewPharmacotherapy2017
Metabolomics as a Driver in Advancing Precision Medicine in Sepsis.
Review in Pharmacotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 70 citations in OpenAlex.
- The molecular ICU: a primer on omics, informatics and the future of precision critical care.Critical care (London, England) · 2026Review
- Integrating metabolomics and machine learning with in silico analysis to identify early biomarkers and molecular interactions in sepsis-associated acute kidney injury.Scientific reports · 2026Article
- A tri-omics and machine learning framework identifies prognostic biomarkers and metabolic signatures in sepsis.Scientific reports · 2026Article
- Metabolic Reprogramming and Immune Metabolism in Sepsis: Targeting the PPAR Pathway for Personalized Therapeutic Approaches.PPAR research · 2026Review
- Early Sepsis Metabolic Changes in Kidney and Liver Precede Clinical Evidence of Organ Dysfunction.American journal of respiratory cell and molecular biology · 2025Article
- Identification and pathway analysis of metabolic biomarkers of gastric acid aspiration-induced lung injury in mice.European journal of medical research · 2025Article
- Integrated Metabolomics and Lipidomics Analysis Reveals the Mechanism Behind the Action of Chiglitazar on the Protection Against Sepsis-Induced Acute Lung Injury.Metabolites · 2025Article
- Advances in metabolomics in critically ill patients with sepsis and septic shock.Clinical and experimental emergency medicine · 2025Article
- The Omics Complexity in Sepsis: The Limits of the Personalized Medicine Approach.Journal of personalized medicine · 2024Review
- Plasma Metabolomics Reveals Distinct Biological and Diagnostic Signatures for Melioidosis.American journal of respiratory and critical care medicine · 2024Article
- Metabolic biomarkers of neonatal sepsis: identification using metabolomics combined with machine learning.Frontiers in cell and developmental biology · 2024Article
- Sepsis, Management & Advances in Metabolomics.Nanotheranostics · 2024Review
- Article
- Sustained Perturbation of Metabolism and Metabolic Subphenotypes Are Associated With Mortality and Protein Markers of the Host Response.Critical care explorations · 2023Article
- Current Limitations of Staph Infection Diagnostics, and the Role for VOCs in Achieving Culture-Independent Detection.Pathogens (Basel, Switzerland) · 2023Review
- The Metabolomics of Critical Illness.Handbook of experimental pharmacology · 2023Article
- Precision Medicine in Sepsis and Septic Shock.Journal of clinical medicine · 2022Article
- Machine learning approaches to the human metabolome in sepsis identify metabolic links with survival.Intensive care medicine experimental · 2022Article
- Diagnosis of Neonatal Sepsis: The Role of Inflammatory Markers.Frontiers in pediatrics · 2022Review
- Knowledge gaps in late-onset neonatal sepsis in preterm neonates: a roadmap for future research.Pediatric research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
The objective of this review is to explain the science of metabolomics-a science of systems biology that measures and studies endogenous small molecules (metabolites) that are present in a single biological sample-and its application to the diagnosis and treatment of sepsis. In addition, we discuss how discovery through metabolomics can contribute to the development of precision medicine targets for this complex disease state and the potential avenues for those new discoveries to be applied in the clinical environment. A nonsystematic literature review was performed focusing on metabolomics, pharmacometabolomics, and sepsis. Human (adult and pediatric) and animal studies were included. Metabolomics has been investigated in the diagnosis, prognosis, and risk stratification of sepsis, as well as for the identification of drug target opportunities. Metabolomics elucidates a new level of detail when compared with other systems biology sciences, with regard to the metabolites that are most relevant in the pathophysiology of sepsis, as well as highlighting specific biochemical pathways at work in sepsis. Metabolomics also highlights biochemical differences between sepsis survivors and nonsurvivors at a level of detail greater than that demonstrated by genomics, transcriptomics, or proteomics, potentially leading to actionable targets for new therapies. The application of pharmacometabolomics and its integration with other systems pharmacology to sepsis therapeutics could be particularly helpful in differentiating drug responders and nonresponders and furthering knowledge of mechanisms of drug action and response. The accumulated literature on metabolomics suggests it is a viable tool for continued discovery around the pathophysiology, diagnosis and prognosis, and treatment of sepsis in both adults and children, and it provides a greater level of biochemical detail and insight than other systems biology approaches. However, the clinical application of metabolomics in sepsis has not yet been fully realized. Prospective validation studies are needed to translate metabolites from the discovery phase into the clinical utility phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.